News

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics

Gyros Protein Technologies introduces Gyrolab CHO-HCP E3G Kit for impurity testing of biotherapeutics

Gyros Protein Technologies and Cygnus Technologies sign licensing and supply agreement

Gyros Protein Technologies installs two Gyrolab xPlore™ systems at Oxford BioMedica for gene and cell therapy applications

Gyros Protein Technologies introduces Gyrolab xPand to improve immunoassay workflow, flexibility and speed in biotherapeutic discovery, development and production

Gyros Protein Technologies and Fleet Bioprocessing partner to offer assay development and transfer services

Gyros Protein Technologies introduces multi-species kit for toxicokinetic studies

Gyros Protein Technologies signs distribution agreement with Euro Diagnostica

Gyros Protein Technologies introduces new ADA solution for immunogenicity market

Gyros Protein Technologies introduces next generation Gyrolab Protein A Kit for Biotherapeutics

Gyros Protein Technologies appoints Mark Vossenaar as Vice President, European Sales

Gyros Protein Technologies signs distribution agreement with Luxembourg Bio Technologies for peptide synthesis reagents

Gyros Protein Technologies introduces a multi-species kit for pharmacokinetic studies

Gyros Protein Technologies appoints Gerrit van den Dool to Board of Directors

Gyros Protein Technologies and Abacus ALS Sign Distribution Agreement

Gyros Protein Technologies establishes dedicated office in Japan

Gyros Protein Technologies Appoints Frank Witney as Chairman

Gyros Protein Technologies Appoints Frank Witney as Chairman

Gyros Protein Technologies Appoints Peter Luk as Vice President, Asia-Pacific

Gyros Protein Technologies Appoints Peter Luk as Vice President, Asia-Pacific

Gyros AB and Protein Technologies, Inc. Merge to Form Gyros Protein Technologies AB

Gyros AB and Protein Technologies, Inc. Merge to Form Gyros Protein Technologies AB

Gyros AB extends capabilities of Gyrolab Automated Immunoassay Platform with New Affinity Software Module

Peptide Mimics as a Drug Target for Ebola: University of Utah Researchers Create a Tool to Develop Treatments for Ebola Using Protein Technologies, Inc.’s Peptide Synthesizer

Gyros introduces a series of kits for bioprocess analysis

Protein Technologies, Inc. and Peptide Solutions, LLC Agree to Drop Their Litigation

Maximized Efficiency in Peptide Synthesis: Protein Technologies, Inc. Unveils Prelude® X with Parallel Six-Channel Rapid Induction Heating

Ampersand Capital Partners Acquires Protein Technologies, Inc.

Gyros Awarded Frost & Sullivan’s 2015 North American Immunoassay Market New Product Innovation Award for Gyrolab xPlore™

Gyros Introduces Gyrolab™ CHO-HCP Kit 1 for Detection and Quantification of Host Cell Proteins in Bioprocessing

Gyros Showcases Nanoliter-scale Immunoassay System Gyrolab xPlore™ at SOT 54th Annual Meeting & ToxExpo™

Gyros Launches Nanoliter-scale Immunoassay System Gyrolab xPlore™ at SLAS2015 Conference

Gyros Launches Gyrolab™ Protein A Kit for Efficient Quantification of Residual Protein A

Gyros and Tekon Biotech Sign Distribution Agreement

EMD Millipore launches new kits for use on Gyros' immunoassay platform

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services

Dan Calvo appointed CEO of Gyros AB; Erik Walldén steps down

Gyros Partners with EMD Millipore to Develop, Manufacture and Commercialize Immunoassay Kits for the Gyrolab™ Platform

Gyros AB Appoints Dr. Claus Braestrup to the Board of Directors

Gyros AB Appoints Dr Henrik Björkman as CTO and VP Technical Affairs

Gyros AB Quality Management System Receives ISO 9001:2008 Certification

Gyros Expands Asian Distribution to Singapore

MPI Research invests in an additional Gyrolab™ xP Workstation

Gyros announces changes to its management team

Gyros introduces new application to monitor anti-drug antibodies during development of biotherapeutics

Gyros and GE Healthcare Life Sciences expand Asian distribution relationship to China, Taiwan and Hong Kong

Gyros completes next stage of development program with expansion of product portfolio

Gyros and GE Healthcare Life Sciences sign distribution agreement for Japan

Gyros wins SwedenBIO Award 2011

Gyros continues positive trend in 2011

Gyros continues expansion into US contract research organizations

Gyros announces availability of Protein A immunoassay kit for Gyrolab xP workstations

Gyros signs three distributor agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs

Gyros introduces new immunoassay kits to improve biotherapeutic development and production workflows

Gyros Platform Chosen by Merck Millipore in Expansion of Contract Service Offerings

Gyros platform integrated into second, US-based, contract research organization

Gyros platform enters leading US Clinical Research Organization

Gyros platform ramps up immunoassay capacity at ICON Development Solutions

Gyros and SCRUM sign distribution agreement for the Japanese market

Gyros and DI Biotech sign distribution agreement for the Korean market

Gyros appoints Dr. Jack Johansen and Mr. Lars Eric Utterman as Non-executives Directors to the Board of Directors

Gyros raises SEK 80 million to accelerate the commercialization of its Gyrolab systems for the cost-efficient development of biopharmaceuticals

MedImmune completes purchase of fifth Gyrolab system to further expand therapeutic antibody development at their west-coast Hayward facility

Gyros launches Gyrolab xP, featuring enhanced ease-of-use, 21 CFR part-11 compliance and extended validation support

Gyros appoints Erik Walldén as CEO

Gyros appoints Katherine Flagg as VP Sales North America

Gyrolab provides strategic advantage to innovative US-based Health and Wellness Company – PPM

Solutions for BioVeris™ owners

Breakthrough sales to German CMO market and continued repeat purchases confirms the importance of Gyrolab for therapeutic antibody development

New CEO at Gyros AB

Gyros completes five new sales of its Gyrolab™ protein quantification platform

Gyros introduces new product for high concentration protein quantification

Gyros named as 2006 Entrepreneurial Company of the Year

Gyros platform for protein quantification purchased by AstraZeneca and Cambridge Antibody Technology

Gyros presented poster at Antibody Production and Development conference in Carlsbad, California

Gyros presented a poster at BioProcess International Conference in Prague

Gyros launches Gyros™ Application Service, the latest addition to the Company’s product portfolio

Gyros AB announces license and development agreement with Fujirebio Inc, Japan

New appointment to boost Gyros sales worldwide

Gyros appoints Jan Würtz as Chief Executive Officer

Gyros and George Washington University step up collaboration

Gyros launches Gyrolab Bioaffy at Drug Discovery and Technology, Boston

Gyros previews next generation of Gyrolab Workstation for protein quantification at nanoliter scale

Gyros introduces new CD microlaboratory for Gyrolab MALDI users.

Gyros AB licenses patented technology to Cellectricon AB.

Gyros AB and Kratos Analytical collaboration is a success

Gyros AB and Kratos Analytical begin development collaboration.

Gyros AB announces first commercial application: Gyrolab™ MALDI.

Gyros AB collaborating with independent cancer research organization to evaluate new technology.

Gyros AB collaborating with independent cancer research organization to evaluate new technology.

Gyros AB and ACE BioSciences A/S reveal proteomics collaboration and begin field tests of prototype.

Gyros AB and Affibody AB announce strategic alliance to develop the world's first microfluidics based protein microarray platform

Genencor International and Gyros AB establish technology collaboration

New start-up company, Gyros AB, completes move to Swedish center of biotechnology and begins expansion.